Contact
searchSearch
HMP Global
Login

Gastrointestinal Stromal Tumors Specialty Channel

Gastrointestinal Stromal Tumors
Specialty Channel
Conference Coverage
Ripretinib for Patients With Advanced GISTs in Later-Line Therapy
02/24/2023
In a multicenter, retrospective study, ripretinib demonstrated clinical activity and was well-tolerated among patients with advanced gastrointestinal stromal tumors who had previously received ≥3 lines of therapy.
In a multicenter, retrospective study, ripretinib demonstrated clinical activity and was well-tolerated among patients with advanced gastrointestinal stromal tumors who had previously received ≥3 lines of therapy.
In a multicenter, retrospective...
02/24/2023
Oncology
News
Similar Survival Outcomes Between Local and Radical Excision for Rectal Gastrointestinal Stromal Tumors
01/19/2023
Among patients with rectal gastrointestinal stromal tumors, local and radical excisions were found to have similar overall survival.
Among patients with rectal gastrointestinal stromal tumors, local and radical excisions were found to have similar overall survival.
Among patients with rectal...
01/19/2023
Oncology
News
Avapritinib Shows Potential for Patients With PDGRFA D842V-Mutant Gastrointestinal Stromal Tumors
12/20/2022
In a phase 1/2 study, avapritinib demonstrated tolerability and anti-tumor activity in patients with gastrointestinal stromal tumors who had platelet-derived growth factor receptor alpha (PDGRFA) D842V mutations.
In a phase 1/2 study, avapritinib demonstrated tolerability and anti-tumor activity in patients with gastrointestinal stromal tumors who had platelet-derived growth factor receptor alpha (PDGRFA) D842V mutations.
In a phase 1/2 study,...
12/20/2022
Oncology
News
Laparoscopic Surgery Demonstrates Feasibility, Safety for Gastrointestinal Stromal Tumors
11/17/2022
Study findings reveal laparoscopic surgery is safe and feasible for patients with gastric gastrointestinal stromal tumors sized between 5 and 8 cm, compared to open surgery.
Study findings reveal laparoscopic surgery is safe and feasible for patients with gastric gastrointestinal stromal tumors sized between 5 and 8 cm, compared to open surgery.
Study findings reveal...
11/17/2022
Oncology
News
Guadecitabine Fails to Meet Target Response Rate in Succinate Dehydrogenase Deficient Gastrointestinal Stromal Tumors
11/10/2022
Phase 2 trial results reveal guadecitabine failed to yield any partial or complete responses in patients with succinate dehydrogenase deficient tumors, including gastrointestinal stromal tumors.
Phase 2 trial results reveal guadecitabine failed to yield any partial or complete responses in patients with succinate dehydrogenase deficient tumors, including gastrointestinal stromal tumors.
Phase 2 trial results reveal...
11/10/2022
Oncology
Quiz
True or False: Ripretinib demonstrated meaningful clinical activity for gastrointestinal stromal tumors after first-line imatinib.
10/18/2022
Did ripretinib demonstrate meaningful clinical activity for patients with advanced gastrointestinal stromal tumors following progression on or intolerance to first-line imatinib? Take our quiz to find out.
Did ripretinib demonstrate meaningful clinical activity for patients with advanced gastrointestinal stromal tumors following progression on or intolerance to first-line imatinib? Take our quiz to find out.
Did ripretinib demonstrate...
10/18/2022
Oncology
News
Ripretinib Provides No PFS Benefit vs Sunitinib for Patients With Advanced Gastrointestinal Stromal Tumors
09/27/2022
Second-line treatment with ripretinib is not associated with improved PFS vs sunitinib for patients with gastrointestinal stromal tumors, however median PFS was comparable between the 2 arms, according to results from the phase 3 INTRIGUE...
Second-line treatment with ripretinib is not associated with improved PFS vs sunitinib for patients with gastrointestinal stromal tumors, however median PFS was comparable between the 2 arms, according to results from the phase 3 INTRIGUE...
Second-line treatment with...
09/27/2022
Oncology
News
Trans-Anal Total Mesorectal Excision Technique Feasible for Rectal Gastrointestinal Stromal Tumors
09/20/2022
In a retrospective study, the use of trans-anal surgery using the trans-anal total mesorectal excision technique was found to be feasible for patients with rectal gastrointestinal stromal tumors.
In a retrospective study, the use of trans-anal surgery using the trans-anal total mesorectal excision technique was found to be feasible for patients with rectal gastrointestinal stromal tumors.
In a retrospective study, the...
09/20/2022
Oncology
News
Comparison of Surgical Methods for Treating Gastrointestinal Stromal Tumors
08/04/2022
Findings from a comparative analysis favor endoscopic full-thickness resection and endoscopic submucosal dissection vs laparoscopic resection for patients with gastrointestinal stromal tumors.
Findings from a comparative analysis favor endoscopic full-thickness resection and endoscopic submucosal dissection vs laparoscopic resection for patients with gastrointestinal stromal tumors.
Findings from a comparative...
08/04/2022
Oncology
News
Study Identifies Factors Associated With GIST Recurrence and Metastasis
08/03/2022
Primary site of tumors, tumor rupture, tumor diameter, risk grade, and mitotic figures were identified as factors associated with postoperative recurrence or metastasis in patients with GIST, according to study findings.
Primary site of tumors, tumor rupture, tumor diameter, risk grade, and mitotic figures were identified as factors associated with postoperative recurrence or metastasis in patients with GIST, according to study findings.
Primary site of tumors, tumor...
08/03/2022
Oncology
News
Preoperative Controlling Nutritional Status Score Predicts Recurrence in Patients With Resected GIST
08/03/2022
Study finds high preoperative controlling nutritional status score is an independent prognostic factor for shorter recurrence-free survival among patients with resected gastrointestinal stromal tumors.
Study finds high preoperative controlling nutritional status score is an independent prognostic factor for shorter recurrence-free survival among patients with resected gastrointestinal stromal tumors.
Study finds high preoperative...
08/03/2022
Oncology

News

Conference Coverage
Ripretinib for Patients With Advanced GISTs in Later-Line Therapy
02/24/2023
In a multicenter, retrospective study, ripretinib demonstrated clinical activity and was well-tolerated among patients with advanced gastrointestinal stromal tumors who had previously received ≥3 lines of therapy.
In a multicenter, retrospective study, ripretinib demonstrated clinical activity and was well-tolerated among patients with advanced gastrointestinal stromal tumors who had previously received ≥3 lines of therapy.
In a multicenter, retrospective...
02/24/2023
Oncology
News
Similar Survival Outcomes Between Local and Radical Excision for Rectal Gastrointestinal Stromal Tumors
01/19/2023
Among patients with rectal gastrointestinal stromal tumors, local and radical excisions were found to have similar overall survival.
Among patients with rectal gastrointestinal stromal tumors, local and radical excisions were found to have similar overall survival.
Among patients with rectal...
01/19/2023
Oncology
News
Avapritinib Shows Potential for Patients With PDGRFA D842V-Mutant Gastrointestinal Stromal Tumors
12/20/2022
In a phase 1/2 study, avapritinib demonstrated tolerability and anti-tumor activity in patients with gastrointestinal stromal tumors who had platelet-derived growth factor receptor alpha (PDGRFA) D842V mutations.
In a phase 1/2 study, avapritinib demonstrated tolerability and anti-tumor activity in patients with gastrointestinal stromal tumors who had platelet-derived growth factor receptor alpha (PDGRFA) D842V mutations.
In a phase 1/2 study,...
12/20/2022
Oncology
News
Laparoscopic Surgery Demonstrates Feasibility, Safety for Gastrointestinal Stromal Tumors
11/17/2022
Study findings reveal laparoscopic surgery is safe and feasible for patients with gastric gastrointestinal stromal tumors sized between 5 and 8 cm, compared to open surgery.
Study findings reveal laparoscopic surgery is safe and feasible for patients with gastric gastrointestinal stromal tumors sized between 5 and 8 cm, compared to open surgery.
Study findings reveal...
11/17/2022
Oncology
News
Guadecitabine Fails to Meet Target Response Rate in Succinate Dehydrogenase Deficient Gastrointestinal Stromal Tumors
11/10/2022
Phase 2 trial results reveal guadecitabine failed to yield any partial or complete responses in patients with succinate dehydrogenase deficient tumors, including gastrointestinal stromal tumors.
Phase 2 trial results reveal guadecitabine failed to yield any partial or complete responses in patients with succinate dehydrogenase deficient tumors, including gastrointestinal stromal tumors.
Phase 2 trial results reveal...
11/10/2022
Oncology
News
Ripretinib Provides No PFS Benefit vs Sunitinib for Patients With Advanced Gastrointestinal Stromal Tumors
09/27/2022
Second-line treatment with ripretinib is not associated with improved PFS vs sunitinib for patients with gastrointestinal stromal tumors, however median PFS was comparable between the 2 arms, according to results from the phase 3 INTRIGUE...
Second-line treatment with ripretinib is not associated with improved PFS vs sunitinib for patients with gastrointestinal stromal tumors, however median PFS was comparable between the 2 arms, according to results from the phase 3 INTRIGUE...
Second-line treatment with...
09/27/2022
Oncology
News
Trans-Anal Total Mesorectal Excision Technique Feasible for Rectal Gastrointestinal Stromal Tumors
09/20/2022
In a retrospective study, the use of trans-anal surgery using the trans-anal total mesorectal excision technique was found to be feasible for patients with rectal gastrointestinal stromal tumors.
In a retrospective study, the use of trans-anal surgery using the trans-anal total mesorectal excision technique was found to be feasible for patients with rectal gastrointestinal stromal tumors.
In a retrospective study, the...
09/20/2022
Oncology
News
Comparison of Surgical Methods for Treating Gastrointestinal Stromal Tumors
08/04/2022
Findings from a comparative analysis favor endoscopic full-thickness resection and endoscopic submucosal dissection vs laparoscopic resection for patients with gastrointestinal stromal tumors.
Findings from a comparative analysis favor endoscopic full-thickness resection and endoscopic submucosal dissection vs laparoscopic resection for patients with gastrointestinal stromal tumors.
Findings from a comparative...
08/04/2022
Oncology
News
Study Identifies Factors Associated With GIST Recurrence and Metastasis
08/03/2022
Primary site of tumors, tumor rupture, tumor diameter, risk grade, and mitotic figures were identified as factors associated with postoperative recurrence or metastasis in patients with GIST, according to study findings.
Primary site of tumors, tumor rupture, tumor diameter, risk grade, and mitotic figures were identified as factors associated with postoperative recurrence or metastasis in patients with GIST, according to study findings.
Primary site of tumors, tumor...
08/03/2022
Oncology
News
Preoperative Controlling Nutritional Status Score Predicts Recurrence in Patients With Resected GIST
08/03/2022
Study finds high preoperative controlling nutritional status score is an independent prognostic factor for shorter recurrence-free survival among patients with resected gastrointestinal stromal tumors.
Study finds high preoperative controlling nutritional status score is an independent prognostic factor for shorter recurrence-free survival among patients with resected gastrointestinal stromal tumors.
Study finds high preoperative...
08/03/2022
Oncology

Interactive Features

Quiz
True or False: Ripretinib demonstrated meaningful clinical activity for gastrointestinal stromal tumors after first-line imatinib.
10/18/2022
Did ripretinib demonstrate meaningful clinical activity for patients with advanced gastrointestinal stromal tumors following progression on or intolerance to first-line imatinib? Take our quiz to find out.
Did ripretinib demonstrate meaningful clinical activity for patients with advanced gastrointestinal stromal tumors following progression on or intolerance to first-line imatinib? Take our quiz to find out.
Did ripretinib demonstrate...
10/18/2022
Oncology
Test Your Knowledge
Quiz: Is There Indication of Decreasing Prevalence of GISTs?
02/24/2022
True or false: Acknowledging GISTs are the most common sarcoma of the GI tract, with estimated incidence between 1.0 and 1.5/100,000 per year, current estimates suggest prevalence decreasing incidences. 
True or false: Acknowledging GISTs are the most common sarcoma of the GI tract, with estimated incidence between 1.0 and 1.5/100,000 per year, current estimates suggest prevalence decreasing incidences. 
True or false: Acknowledging...
02/24/2022
Oncology
Test Your Knowledge
Quiz: Recommended Treatment Options for c-KIT, PDGFRA Wild-Type GIST
02/18/2022
True or false: Typically, clinical trials or targeted therapies are recommended for patients with c-KIT and PDGFRA wild-type GIST who are unable to obtain multi-target protein tyrosine kinase inhibitors therapy.
True or false: Typically, clinical trials or targeted therapies are recommended for patients with c-KIT and PDGFRA wild-type GIST who are unable to obtain multi-target protein tyrosine kinase inhibitors therapy.
True or false: Typically,...
02/18/2022
Oncology
Quiz
Quiz: Which Diagnosis Method Provides Better Aid for Patients with GIST?
08/11/2021
Which method is confirmed to provide better aid in the diagnosis of GIST therapy?
Which method is confirmed to provide better aid in the diagnosis of GIST therapy?
Which method is confirmed to...
08/11/2021
Oncology
Quiz
Quiz: Is There a Correlation Between High-Risk GIST and Chromosomal Complexity?
08/10/2021
True or false: In localized, high-risk GIST, patients with chromosomal complexities have poor RFS.
True or false: In localized, high-risk GIST, patients with chromosomal complexities have poor RFS.
True or false: In localized,...
08/10/2021
Oncology
Interactive Features
Quiz: Are There Possible Clinical Differences in Multiple Vs Single GISTs?
06/02/2021
True or False: Findings from a retrospective analysis suggest the clinical features and treatment approaches for multiple gastrointestinal stromal tumors (MGISTs) may differ from single GISTs, ultimately presenting a gap in the treatment...
True or False: Findings from a retrospective analysis suggest the clinical features and treatment approaches for multiple gastrointestinal stromal tumors (MGISTs) may differ from single GISTs, ultimately presenting a gap in the treatment...
True or False: Findings from a...
06/02/2021
Oncology
Test Your Knowledge
Quiz: Genetic Vs Sporadic Diagnosis in GIST
05/03/2021
True or False: A genetic diagnosis yields benefit in gastrointestinal stromal tumor therapy by informing the patient and provider(s) of the possibility for other malignancies, suggested surveillance, management for other NF1 comorbidities,...
True or False: A genetic diagnosis yields benefit in gastrointestinal stromal tumor therapy by informing the patient and provider(s) of the possibility for other malignancies, suggested surveillance, management for other NF1 comorbidities,...
True or False: A genetic...
05/03/2021
Oncology
Test Your Knowledge
Quiz: How is Ripretinib Designed to Treat GIST?
04/07/2021
True or false: Ripretinib is a novel switch-control kinase inhibitor designed to inhibit a wide range of KIT and PDGFRA mutations.
True or false: Ripretinib is a novel switch-control kinase inhibitor designed to inhibit a wide range of KIT and PDGFRA mutations.
True or false: Ripretinib is a...
04/07/2021
Oncology
Test Your Knowledge
Quiz: Adjuvant Imatinib for High-Risk GIST
03/29/2021
True or false: Prolonged adjuvant imatinib therapy extends overall survival in patients with high-risk GIST.
True or false: Prolonged adjuvant imatinib therapy extends overall survival in patients with high-risk GIST.
True or false: Prolonged...
03/29/2021
Oncology
Test Your Knowledge
Quiz: Treatment Options for Stage IV GIST
02/09/2021
Which of the following combination treatment options has yielded the best outcomes in patients with stage IV GIST?
Which of the following combination treatment options has yielded the best outcomes in patients with stage IV GIST?
Which of the following...
02/09/2021
Oncology

Recent News

News
Similar Survival Outcomes Between Local and Radical Excision for Rectal Gastrointestinal Stromal Tumors
01/19/2023
Among patients with rectal gastrointestinal stromal tumors, local and radical excisions were found to have similar overall survival.
Among patients with rectal gastrointestinal stromal tumors, local and radical excisions were found to have similar overall survival.
Among patients with rectal...
01/19/2023
Oncology
News
Avapritinib Shows Potential for Patients With PDGRFA D842V-Mutant Gastrointestinal Stromal Tumors
12/20/2022
In a phase 1/2 study, avapritinib demonstrated tolerability and anti-tumor activity in patients with gastrointestinal stromal tumors who had platelet-derived growth factor receptor alpha (PDGRFA) D842V mutations.
In a phase 1/2 study, avapritinib demonstrated tolerability and anti-tumor activity in patients with gastrointestinal stromal tumors who had platelet-derived growth factor receptor alpha (PDGRFA) D842V mutations.
In a phase 1/2 study,...
12/20/2022
Oncology
News
Laparoscopic Surgery Demonstrates Feasibility, Safety for Gastrointestinal Stromal Tumors
11/17/2022
Study findings reveal laparoscopic surgery is safe and feasible for patients with gastric gastrointestinal stromal tumors sized between 5 and 8 cm, compared to open surgery.
Study findings reveal laparoscopic surgery is safe and feasible for patients with gastric gastrointestinal stromal tumors sized between 5 and 8 cm, compared to open surgery.
Study findings reveal...
11/17/2022
Oncology
News
Guadecitabine Fails to Meet Target Response Rate in Succinate Dehydrogenase Deficient Gastrointestinal Stromal Tumors
11/10/2022
Phase 2 trial results reveal guadecitabine failed to yield any partial or complete responses in patients with succinate dehydrogenase deficient tumors, including gastrointestinal stromal tumors.
Phase 2 trial results reveal guadecitabine failed to yield any partial or complete responses in patients with succinate dehydrogenase deficient tumors, including gastrointestinal stromal tumors.
Phase 2 trial results reveal...
11/10/2022
Oncology
News
Ripretinib Provides No PFS Benefit vs Sunitinib for Patients With Advanced Gastrointestinal Stromal Tumors
09/27/2022
Second-line treatment with ripretinib is not associated with improved PFS vs sunitinib for patients with gastrointestinal stromal tumors, however median PFS was comparable between the 2 arms, according to results from the phase 3 INTRIGUE...
Second-line treatment with ripretinib is not associated with improved PFS vs sunitinib for patients with gastrointestinal stromal tumors, however median PFS was comparable between the 2 arms, according to results from the phase 3 INTRIGUE...
Second-line treatment with...
09/27/2022
Oncology
News
Trans-Anal Total Mesorectal Excision Technique Feasible for Rectal Gastrointestinal Stromal Tumors
09/20/2022
In a retrospective study, the use of trans-anal surgery using the trans-anal total mesorectal excision technique was found to be feasible for patients with rectal gastrointestinal stromal tumors.
In a retrospective study, the use of trans-anal surgery using the trans-anal total mesorectal excision technique was found to be feasible for patients with rectal gastrointestinal stromal tumors.
In a retrospective study, the...
09/20/2022
Oncology
News
Comparison of Surgical Methods for Treating Gastrointestinal Stromal Tumors
08/04/2022
Findings from a comparative analysis favor endoscopic full-thickness resection and endoscopic submucosal dissection vs laparoscopic resection for patients with gastrointestinal stromal tumors.
Findings from a comparative analysis favor endoscopic full-thickness resection and endoscopic submucosal dissection vs laparoscopic resection for patients with gastrointestinal stromal tumors.
Findings from a comparative...
08/04/2022
Oncology
News
Study Identifies Factors Associated With GIST Recurrence and Metastasis
08/03/2022
Primary site of tumors, tumor rupture, tumor diameter, risk grade, and mitotic figures were identified as factors associated with postoperative recurrence or metastasis in patients with GIST, according to study findings.
Primary site of tumors, tumor rupture, tumor diameter, risk grade, and mitotic figures were identified as factors associated with postoperative recurrence or metastasis in patients with GIST, according to study findings.
Primary site of tumors, tumor...
08/03/2022
Oncology
News
Preoperative Controlling Nutritional Status Score Predicts Recurrence in Patients With Resected GIST
08/03/2022
Study finds high preoperative controlling nutritional status score is an independent prognostic factor for shorter recurrence-free survival among patients with resected gastrointestinal stromal tumors.
Study finds high preoperative controlling nutritional status score is an independent prognostic factor for shorter recurrence-free survival among patients with resected gastrointestinal stromal tumors.
Study finds high preoperative...
08/03/2022
Oncology
News
Bridging Study Finds Ripretinib Improves Survival Among Chinese Patients With Advanced Gastrointestinal Stromal Tumors
07/08/2022
In a phase 2 bridging study of the phase 3 INVICTUS study, ripretinib was found to improve the survival of Chinese patients with advanced gastrointestinal stromal tumors.
In a phase 2 bridging study of the phase 3 INVICTUS study, ripretinib was found to improve the survival of Chinese patients with advanced gastrointestinal stromal tumors.
In a phase 2 bridging study of...
07/08/2022
Oncology
News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
11/12/2024
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial,...
11/12/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma
11/05/2024
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study...
11/05/2024
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use